biobanking: challenges, solutions, and potential microsampling applications
by Emerson Dameron, on Dec 22, 2017 5:28:00 AM
What is Microsampling?
Advances in bioanalysis now allow for the assessment of drug and chemical exposure from smaller specimen samples than ever before. With Volumetric Absorptive Microsampling (VAMS™) technology, dependable data can be obtained from specimens as small as 10-20 µL.
What Dried Blood Microsampling Means for Biobanking
The use of dried specimens introduces a new flexibility into the operational aspects of precision medicine biobanking. This new sampling technology is amenable to use in settings with limited transport and storage options, wherein infrastructure, resources, and environmental factors are not condusive to traditional sampling methods.
Biobanking Challenges | Microsampling Solutions
As change accelerates, sustainability is an essential metric for measuring a biobank's value over time. To achieve continuing research success and value to the public, biobanks must place a renewed emphasis on sustainability. This requires making plans today to grow, remain profitable, and adapt to changing protocols and technology.
Solution: Plan For The Future
The simpler, smarter microsampling workflow is uniquely well suited to increasing sustainability challenges in a more tightly networked biobanking ecosystem. Biobanks that adopt microsampling technology now will simplify operations, preserve resources, and open new options for future growth.
Challenge: Collaborative Research
There is an increasing expectation that biobanks drive science. Biobanks must shift from a focus on primarily operational and in-house sample inventory management activities (hoarding samples) to driving scientific insights by encouraging proper utilization of samples. Linking biospecimens with patient clinical and molecular data is now critical.
Solution: Microsampling Cost Savings
Microsampling can streamline operations and facilitate the collection of valuable data while saving time, expense, and labor. Stored dried blood samples have been shown to yield data comparable to that generated by wet blood; its adoption makes things easier without sacrificing quality.
Challenge: Regulatory Compliance
Security is paramount. The sensitive nature of clinical research requires aggressive privacy control and regulatory compliance for human samples. As scientific discoveries increasingly rely on sample-based biomarker data, greater scrutiny is placed upon stringent adherence to governing standards.
Solution: Streamline workflows
Microsampling is part of an movement towards simplification, with regulatory compliance baked into workflow. The convenience of Mitra® collection devices can aid in efforts toward compliance with regulations such as HIPAA, 21CFR Part 11, GxP, CAP, and CLIA.